Association of breast cancer outcome with status of p53 and MDM2 SNP309.

BACKGROUND A common single-nucleotide polymorphism (SNP) in the promoter region of the MDM2 gene, known as T-309G and referred to as SNP309 for this study, leads to increased expression of Mdm2 protein and attenuated function of the p53 tumor suppressor protein. We investigated whether genetic variants in MDM2 were associated with breast cancer incidence and survival and whether the variant status could interact with the tumor p53 status to modify breast cancer survival. METHODS We used multivariable logistic and Cox regression analyses to study the relationship of SNP309 status and the status of a second MDM2 SNP in exon 12 at codon 354 (SNP354) with breast cancer incidence and with disease-specific survival among 293 case patients and 317 cancer-free control subjects. Survival analysis included 248 of the 293 case patients who had known tumor p53 status. All statistical tests were two-sided. RESULTS We did not observe an association between SNP309 status and breast cancer incidence in the unstratified analysis, but we did find a statistically significant association between SNP354 status and breast cancer incidence (odds ratio = 3.34, 95% confidence interval [CI] = 1.88 to 5.93). We also discovered a statistically significant interaction between SNP309 status and tumor p53 expression for breast cancer survival (P(interaction) = .002). Among homozygous carriers of the common MDM2 SNP309 allele (T/T), a mutant p53 status (risk ratio [RR] of death = 2.33, 95% CI = 1.08 to 5.03) and aberrant p53 protein expression (RR = 2.61, 95% CI = 1.22 to 5.57) in breast tumors were associated with poor survival. Tumor p53 status was not associated with breast cancer survival among carriers of the variant MDM2 SNP309 allele (G/T or G/G), which is consistent with a dominant effect of the variant allele. CONCLUSION A strong interaction between SNP309 status and tumor p53 status appears to modify the association between p53 status and breast cancer survival.

[1]  Hongbing Shen,et al.  Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. , 2006, Cancer letters.

[2]  D. Eccles,et al.  No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. , 2006, Cancer letters.

[3]  R. Bertorelle,et al.  Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. , 2006, Journal of the National Cancer Institute.

[4]  P. Bugert,et al.  The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer. , 2006, Cancer research.

[5]  R. Millikan,et al.  No Association Between the MDM2 −309 T/G Promoter Polymorphism and Breast Cancer in African-Americans or Whites , 2006, Cancer Epidemiology Biomarkers & Prevention.

[6]  C. Harris,et al.  Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans. , 2005, Cancer research.

[7]  A. Levine,et al.  A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells* , 2005, Journal of Biological Chemistry.

[8]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[9]  Hui Wang,et al.  MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. , 2005, Current cancer drug targets.

[10]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[11]  E. Bowman,et al.  Diet and alcohol consumption in relation to p53 mutations in breast tumors. , 2004, Carcinogenesis.

[12]  U. Moll,et al.  The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.

[13]  Nicole Benoit,et al.  p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. , 2003, Journal of the National Cancer Institute.

[14]  C. Cordon-Cardo,et al.  Lack of p53 Nuclear Immunostaining Is Not Indicative of Absence of TP53 Gene Mutations in Colorectal Adenocarcinomas , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[15]  A. Børresen-Dale,et al.  TP53 and breast cancer , 2003, Human mutation.

[16]  L. Mayo,et al.  The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. , 2002, Trends in biochemical sciences.

[17]  G. Landberg,et al.  The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node , 2002, Oncogene.

[18]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[19]  Moshe Oren,et al.  The p53 and Mdm2 families in cancer. , 2002, Current opinion in genetics & development.

[20]  S. Deb,et al.  The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants. , 2001, International journal of oncology.

[21]  Y. Soini,et al.  Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  C Caldas,et al.  Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis , 1999, British Journal of Cancer.

[23]  J. Willey,et al.  Alterations of p53 in tumorigenic human bronchial epithelial cells correlate with metastatic potential. , 1999, Carcinogenesis.

[24]  J. Primrose,et al.  Optimisation of DNA and RNA extraction from archival formalin-fixed tissue. , 1999, Nucleic acids research.

[25]  J. Jen,et al.  Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[27]  W D Plummer,et al.  Power and sample size calculations for studies involving linear regression. , 1998, Controlled clinical trials.

[28]  M. Toi,et al.  MDM2 in breast cancer , 1997, Breast cancer.

[29]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[30]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[31]  J. Eyfjörd,et al.  TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. , 1995, European journal of cancer.

[32]  J. Jett,et al.  Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. , 1995, Carcinogenesis.

[33]  T. Visakorpi,et al.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. , 1992, Journal of the National Cancer Institute.

[34]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[35]  William D. Dupont,et al.  Power and sample size calculations. A review and computer program. , 1990, Controlled clinical trials.

[36]  L. Liotta,et al.  Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  Brian Staats,et al.  SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes , 2004, Nucleic Acids Res..